Results 81 to 90 of about 432,438 (233)

Carcinome métaplasique du sein : à propos d’un cas

Avicenna Medical Research
Le carcinome métaplasique du sein est une tumeur maligne primaire rare et agressive, représentant 0,2- 5% de tous les cancers du sein. Cette tumeur maligne est caractérisée par la présence histologique d'au moins deux types cellulaires, généralement ...
K.N LARDJANE, T MERABTI, R KEDJEM, B LAZIZI, W ABBACI, R TOUAT, N LALOUTI, M RAMOUL, A DJADJOUA, R BOUZOUAGH, C BOUZID   +10 more
doaj  

Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases

Journal of Bone Oncology
Background: Bone metastasis is a significant concern in advanced solid tumors, contributing to diminished patient survival and quality of life due to skeletal-related events (SREs). Denosumab (DMAB), a monoclonal antibody targeting the receptor activator
E. Mabrut, S. Mainbourg, J. Peron, D. Maillet, S. Dalle, C. Fontaine Delaruelle, E. Grolleau, P. Clezardin, E. Bonnelye, C.B. Confavreux, E. Massy   +10 more
doaj   +1 more source

Des métastases osseuses d'un mélanome malin détectées sur une TEP au 18F-FDG avec scintigraphie du squelette normale

The Pan African Medical Journal, 2017
Nous rapportons le cas d'une patiente âgée de 30 ans, opérée deux ans plus tôt pour un mélanome de la fesse droite et qui a consulté pour les douleurs rachidiennes persistantes. La scintigraphie osseuse (SO) était tout à fait normale (A).
Abderrahim Doudouh, Abdelhamid Biyi
doaj   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Dissociated skeletal response to first-line immunotherapy in synchronous bone metastatic non-small cell lung cancer patients: Clinical profiles and survival benefit of denosumab adjunction

Journal of Bone Oncology
Introduction: Patients with bone metastases (BM) from non-small cell lung cancer (NSCLC) derive less clinical benefit from immune checkpoint inhibitors (ICIs) than those without skeletal involvement. We aimed to characterize bone-specific disease control
E. Massy, N. Stacoffe, M. Fauvernier, M. Duruisseaux, E. Grolleau, M. Lamkhioued, M. Pérol, C. Domblides, M. Roche, A. Stuani, P. Clézardin, E. Bonnelye, J.B. Pialat, N. Girard, C. Confavreux   +14 more
doaj   +1 more source

Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant

Cancer Medicine, 2019
Background Endocrine therapy is the preferred treatment for patients with hormone receptor ‐positive metastatic breast cancer (MBC). While visceral metastasis is a negative prognostic factor, few studies have distinguished between the prognoses of ...
Min He, Jun‐Jie Li, Wen‐Jia Zuo, Lei Ji, Yi‐Zhou Jiang, Xi‐Chun Hu, Zhong‐Hua Wang, Zhi‐Ming Shao   +7 more
doaj   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

Molecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

Les métastases pulmonaires : quelle place pour la chirurgie d 'exérèse ?

, 1999
L'exérèse chirurgicale de métastases pulmonaires s'applique à des patients sélectionnés en fonction de leur réserve fondionnelle, du type de tumeur primaire, de la vitesse d'évolution de celle-ci et du mode de présentation de la maladie métastatique. Les
Reynard, C., Leuenberger, P., Ris, H. B.
core   +1 more source